Immunron skyrockets over 100% on revenue surge in Q4

318
Immunron

Shares of biopharmacuetical company Immunron (NASDAQ: IMRN) shot up over 100% in the premarket following the release of their fourth quarter results.

  • Immunron shares were higher on elevated volume after they posted a 52% jump in North American sales that hit $1.16 million.
  • Travelan sales were up 32% and sales in Canada were up over $100k for Q4.

Company Profile

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company’s lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty-liver diseases.



NO COMMENTS

LEAVE A REPLY